Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
861 to 880 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Proteolytic Processing of the Coronavirus Replicase Nonstructural Protein 14 Exonuclease Is Not Required for Virus Replication but Alters RNA Synthesis and Viral Fitness. | J Virol | 2022 | 35924922 | PubTator, text mining | PubMed |
| Oral Supplementation of Houttuynia cordata Extract Reduces Viremia in PRRSV-1 Modified-Live Virus-Vaccinated Pigs in Response to the HP-PRRSV-2 Challenge. | Front Immunol | 2022 | 35924249 | PubTator, text mining | PubMed |
| Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. | MedComm (2020) | 2022 | 35923762 | PubTator, text mining | PubMed |
| Targeting SARS-CoV-2 endoribonuclease: a structure-based virtual screening supported by in vitro analysis. | Sci Rep | 2022 | 35922447 | PubTator, text mining | PubMed |
| Trafficked Malayan pangolins contain viral pathogens of humans. | Nat Microbiol | 2022 | 35918420 | PubTator, text mining | PubMed |
| A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease. | Neurotox Res | 2022 | 35917086 | PubTator, text mining | PubMed |
| Porcine Deltacoronavirus Infection Cleaves HDAC2 to Attenuate Its Antiviral Activity. | J Virol | 2022 | 35916536 | PubTator, text mining | PubMed |
| Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019-2022. | PLoS One | 2022 | 35913920 | PubTator, text mining | PubMed |
| Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation. | Front Med (Lausanne) | 2022 | 35911386 | PubTator, text mining | PubMed |
| Genetic Characterization of a Novel Bovine Rotavirus A G37P[52] Closely Related to Human Strains. | Front Vet Sci | 2022 | 35909675 | PubTator, text mining | PubMed |
| (+)-Usnic acid and its salts, inhibitors of SARS-CoV-2, identified by using in silico methods and in vitro assay. | Sci Rep | 2022 | 35908082 | PubTator, text mining | PubMed |
| "Flash & Click": Multifunctionalized Lipid Derivatives as Tools To Study Viral Infections. | J Am Chem Soc | 2022 | 35900117 | PubTator, text mining | PubMed |
| Research Progress on the NSP9 Protein of Porcine Reproductive and Respiratory Syndrome Virus. | Front Vet Sci | 2022 | 35898550 | PubTator, text mining | PubMed |
| Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma. | Front Immunol | 2022 | 35898502 | PubTator, text mining | PubMed |
| Covariance predicts conserved protein residue interactions important for the emergence and continued evolution of SARS-CoV-2 as a human pathogen. | PLoS One | 2022 | 35895734 | PubTator, text mining | PubMed |
| Composition of naturally occurring compounds decreases activity of Omicron and SARS-CoV-2 RdRp complex. | Eur J Microbiol Immunol (Bp) | 2022 | 35895480 | PubTator, text mining | PubMed |
| TRIM7 Restricts Coxsackievirus and Norovirus Infection by Detecting the C-Terminal Glutamine Generated by 3C Protease Processing. | Viruses | 2022 | 35893676 | PubTator, text mining | PubMed |
| A Comparison of Bioinformatics Pipelines for Enrichment Illumina Next Generation Sequencing Systems in Detecting SARS-CoV-2 Virus Strains. | Genes (Basel) | 2022 | 35893066 | PubTator, text mining | PubMed |
| The Inhibitory Potential of Ferulic Acid Derivatives against the SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics, and ADMET Evaluation. | Biomedicines | 2022 | 35892687 | PubTator, text mining | PubMed |
| Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. | J Diabetes Metab Disord | 2022 | 35891981 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=44